TRIB
Trinity Biotech plc
NASDAQ · Healthcare · Medical - Diagnostics & Research · IE
$9.41
−1.98%Year over year
Reported trailing growth
- Revenue
- -28.7%
- EBITDA
- +49.3%
- EBIT
- +46.8%
- EPS
- -61.9%
- Free cash flow
- +61.0%
- Operating cash flow
- -1.0%
Forward estimates
Based on analyst estimates
- Revenue
- -55.4%
- EBITDA
- +153.7%
- EPS
- +74.3%
Three-year CAGR
- Revenue
- -11.2%
- EBITDA
- -26.5%
- EBIT
- +46.1%
- Net income
- -17.6%
- EPS
- -13.3%
- Free cash flow
- +14.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025